RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences

RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage biopharmaceutical company based in South San Francisco, is set to actively engage with the investment community this September through participation in several prominent investor conferences. The company specializes in developing innovative therapies targeted at patients suffering from inflammatory and immunological diseases, leveraging its strong expertise in immunology to create therapies that effectively modulate immune responses.

The RAPT management team plans to take part in the following events:

1. **Wells Fargo Healthcare Conference**: A fireside chat scheduled for September 3, 2025, at 12:45 p.m. ET. 2. **Cantor Global Healthcare Conference 2025**: Another fireside chat to take place on September 4, 2025, at 1:00 p.m. ET. 3. **H.C. Wainwright 27th Annual Global Investment Conference**: They will also conduct a fireside chat on September 9, 2025, at 9:00 a.m. ET. 4. **Stifel 2025 Virtual Immunology & Inflammation Forum**: RAPT will deliver a presentation on September 15, 2025, at 9:30 a.m. ET.

Interested investors can access these live webcasts and later recordings via the RAPT Therapeutics website at [https://investors.rapt.com/events-and-presentations](https://investors.rapt.com/events-and-presentations). The company's dedication to advancing treatments in the immunology space is underscored by its strategic outreach during these key events, showcasing its commitment to innovation in the healthcare sector. For any inquiries, Sylvia Wheeler from the investor relations team and Aljanae Reynolds for media relations are available for contact.

RAPT Therapeutics, Inc. (NASDAQ: RAPT) has positioned itself strategically at the intersection of immunology and biopharmaceuticals, focusing on innovative therapies for inflammatory and immunological diseases. With upcoming participation in multiple prominent investor conferences in September 2025, the company presents an interesting opportunity for investors looking to capitalize on developments in this high-growth sector.

The investor engagements scheduled at the Wells Fargo Healthcare Conference, Cantor Global Healthcare Conference, H.C. Wainwright 27th Annual Global Investment Conference, and Stifel Virtual Immunology & Inflammation Forum should provide valuable insights into RAPT's pipeline, particularly their advancements in therapies that leverage proprietary immunological expertise. Such platforms often serve as catalysts for increased investor interest, potentially leading to upward price movement.

From a financial analysis perspective, investors should closely monitor the pipeline data that may arise from these presentations. Any updates on clinical trial results or therapeutic breakthroughs can have significant impacts on RAPT’s market valuation. The excitement in the biopharmaceutical sector is often driven by these pivotal news releases, especially when dealing with novel therapies in a landscape that is witnessing increased demand for innovative treatments.

Furthermore, the timing of these conferences, just as RAPT is progressing through its clinical stage, highlights an opportunity for investors to gauge the management’s commitment to transparency and stakeholder engagement. Additionally, if RAPT is able to secure partnerships or funding announcements during these events, it could provide additional growth avenues.

In conclusion, potential investors should consider incorporating RAPT Therapeutics into their portfolios, particularly in anticipation of insights that will emerge from the upcoming conferences. Close monitoring of the stock's performance post-conference can further refine investment timing decisions in this promising biopharmaceutical cycle.